Related content

Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer

By Ishikawa Hajime   Imano Motohiro   Shiraishi Osamu   Yasuda Atsushi   Peng Ying-Feng   Shinkai Masayuki   Yasuda Takushi   Imamoto Haruhiko   Shiozaki Hitoshi  

Gastric Cancer, Vol. 17, Iss. 1, 2014-01 ,pp. : 173-180

Springer Publishing Company

Access to resources Recommend Favorite

Vaccination with HPV16 Peptides of Patients with Advanced Cervical Carcinoma: Clinical Evaluation of a Phase I-II Trial

By van Driel W.J.   Ressing M.E.   Kenter G.G.   Brandt R.M.P.   Krul E.J.T.   van Rossum A.B.   Schuuring E.   Offringa R.   Bauknecht T.   Tamm-Hermelink A.   van Dam P.A.   Fleuren G.J.   Kast W.M.   Melief C.J.M.   Trimbos J.B.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 946-952

Elsevier

Access to resources Recommend Favorite

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

By Svane Inge   Pedersen Anders   Johnsen Hans   Nielsen Dorte   Kamby Claus   Gaarsdal Eva   Nikolajsen Kirsten   Buus Søren   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

By Romero Pedro   Cerottini Jean-Charles   Speiser Daniel  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 249-255

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

By                    

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 109-117

Spandidos Publications

Access to resources Recommend Favorite